1. Home
  2. WVE vs SLNO Comparison

WVE vs SLNO Comparison

Compare WVE & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$13.25

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Logo Soleno Therapeutics Inc.

SLNO

Soleno Therapeutics Inc.

N/A

Current Price

$39.72

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WVE
SLNO
Founded
2012
1999
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.3B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
WVE
SLNO
Price
$13.25
$39.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
11
Target Price
$30.87
$108.00
AVG Volume (30 Days)
2.2M
1.3M
Earning Date
05-29-2026
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
108.90
EPS
N/A
0.39
Revenue
$3,704,000.00
$1,450,788.00
Revenue This Year
N/A
$155.44
Revenue Next Year
$119.93
$57.99
P/E Ratio
N/A
$101.46
Revenue Growth
149.43
138.82
52 Week Low
$5.28
$32.63
52 Week High
$21.73
$89.12

Technical Indicators

Market Signals
Indicator
WVE
SLNO
Relative Strength Index (RSI) 47.06 48.68
Support Level $12.53 $38.17
Resistance Level $14.56 $41.86
Average True Range (ATR) 0.79 2.23
MACD -0.04 0.26
Stochastic Oscillator 26.10 76.81

Price Performance

Historical Comparison
WVE
SLNO

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Share on Social Networks: